New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTHK, FRX, AWI, WETF, ORLY, PFE, MRK, FRC, CVX, AGN, ZNGA, OPEN, GILD, DRE, CBT, OIS, CRM, NLSN, GPS, DVN, ANGIOn the Fly: Analyst Upgrade Summary
Allergan (AGN) upgraded to Buy from Neutral at Citigroup... Angie's List (ANGI) upgraded to Outperform from Market Perform at Barrington... Cabot (CBT) upgraded to Buy from Neutral at SunTrust... Chevron (CVX) upgraded to Strong Buy from Outperform at Raymond James... Devon Energy (DVN) upgraded to Outperform from Neutral at Credit Suisse... Duke Realty (DRE) upgraded to Outperform from Sector Perform at RBC Capital... First Republic (FRC) upgraded to Outperform from Market Perform at Keefe Bruyette,,, Gap (GPS) upgraded to Buy from Neutral at UBS... Gilead (GILD) upgraded to Outperform from Neutral at RW Baird... Merck (MRK) upgraded to Buy from Neutral at SunTrust... Nielsen (NLSN) upgraded to Buy from Hold at Pivotal Research... OpenTable (OPEN) upgraded to Neutral from Sell at Citigroup... Pfizer (PFE) upgraded to Buy from Hold at Jefferies... Salesforce.com (CRM) upgraded to Buy from Neutral at Roth Capital... Zynga (ZNGA) upgraded to Buy from Neutral at UBS... O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast... Oil States (OIS) upgraded to Buy from Accumulate at Tudor Pickering... Armstrong World (AWI) upgraded to Buy from Hold at Gabelli... Halcon Resources (HK) upgraded to Neutral from Reduce at Global Hunter... Wisdom Tree (WETF) upgraded to Buy from Neutral at BofA/Merrill... Forest Labs (FRX) upgraded to Overweight from Neutral at JPMorgan.
News For AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 12, 2015
14:51 EDTCVXSaudi Prince Alwaleed says oil won't hit $100 again, USA Today reports
Oil will never reach a price of $100 per barrel again, Saudi billionaire businessman Prince Alwaleed bin Talal said, according to USA Today. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
12:45 EDTPFEActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
12:05 EDTANGIWeitz Investment reports 6.29% passive stake in Angie's List
Subscribe for More Information
10:30 EDTZNGAStocks with call strike movement; RIG ZNGA
Transocean (RIG) May 17 call option implied volatility increased 10% to 79, Zynga (ZNGA) June 3 call option implied volatility increased 4% to 64 according to IVolatility.
10:00 EDTHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:37 EDTAGNSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
09:34 EDTGILDActive equity options trading
Subscribe for More Information
09:32 EDTORLYO'Reilly Automotive downgraded to Neutral from Buy at Northcoast
Subscribe for More Information
09:22 EDTPFE23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
09:00 EDTHKHalcon Resources downgraded to Equal Weight from Overweight at Stephens
Subscribe for More Information
08:37 EDTPFE, MRKShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:09 EDTAGNActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTAGNActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information
07:21 EDTMRKEBD Group to hold a conference
Subscribe for More Information
07:07 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:05 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
07:04 EDTMRKMerck sees NDA submission for Hepatitis C combination regimen in 1H15
Subscribe for More Information
07:03 EDTMRKMerck says targeted cost savings on track to be realized by end 2015
Subscribe for More Information
06:53 EDTMRKMerck to speed up plans for drug submission, WSJ says
Merck is speeding up its plans to submit new drugs for lung cancer and hepatitis C for regulatory approval, reports the Wall Street Journal. The company will file an application with the FDA around the mid-2015 to expand the use of Keytruda, the Journal adds. Reference Link
06:22 EDTMRKWHO approves 2 ebola vaccines to enter West Africa trials, Financial Times says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use